Welcome to Sabbiotech!     
Email:info@signalwayantibody.com
Location: Home > Conjugated Antibodies > NFKB p65 Antibody FITC Conjugated

NFKB p65 Antibody FITC Conjugated#C00285F

Availability: 15 business days.
Total Amount:$
Product Detail

Product NameNFKB p65 Antibody FITC Conjugated

Host SpeciesRabbit

ClonalityPolyclonal

IsotypeIgG

PurificationPurified by Protein A.

ApplicationsFlow-Cyt IF

Species ReactivityHu Ms Rt

Immunogen DescKLH conjugated synthetic peptide aa 50-100 551 derived from human NFKBp65

Target NameNFKB p65

ConjugateFITC

Excitation Emission494nm 518nm

Other Namesp65; NFKB3; Transcription factor p65; Nuclear factor NF-kappa-B p65 subunit; Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3; RELA

Accession NoSwiss-Prot#Q04206
NCBI Gene ID5970

Uniprot Q04206

Gene ID 5970;

Concentration1mg ml

Formulation0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.

StorageShipped at 4˚C. Store at -20˚C for one year. Avoid repeated freeze/thaw cycles.

Application Details
Flow-Cyt=1:50-200 IF=1:50-200
NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA p65, RELB, NFKB1 p15, NFKB1 p5, REL and NFKB2 p52 and the heterodimeric p65-p5 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p5 and p65-c-Rel complexes are transcriptional activators. The NF-kappa-B p65-p65 complex appears to be involved in invasin-mediated activation of IL-8 expression. The inhibitory effect of I-kappa-B upon NF-kappa-B the cytoplasm is exerted primarily through the interaction with p65. p65 shows a weak DNA-binding site which could contribute directly to DNA binding in the NF-kappa-B complex. Associates with chromatin at the NF-kappa-B promoter region via association with DDX1.

If you have published an article using product C00285F, please notify us so that we can cite your literature.

NOTE

Application

  • WBWestern Blotting
  • IHCImmunohistochemistry
  • IFImmunofluorescence
  • ICCImmunocytochemistry
  • FCFlow Cytometry
  • IPImmunoprecipitation
  • EELISA
  • DBDot Blotting
  • ChIPChromatin Immunoprecipitation
  • GICAGold Immunochromatography Assay
  • NCNegative Control

Species Reactivity

  • HuHuman
  • MsMouse
  • RtRat
  • DmDrosophila melanogaster
  • CCaenorhabditis elegans
  • MkMonkey
  • RbRabbit
  • BBovine
  • DDog
  • PPig
  • HmHamster
  • ChHmChinese Hamster
  • ChkChicken
  • ShpSheep
;